DDInter1035 DDInter1376
Lenalidomide (previously referred to as CC-5013) is an immunomodulatory drug with potent antineoplastic, anti-angiogenic, and anti-inflammatory properties. It is a 4-amino-glutamyl analogue of [thalidomide] and like thalidomide, lenalidomide exists as a racemic mixture of the active S(-) and R(+) forms. However, lenalidomide is much safer and potent than thalidomide, with fewer adverse effects and toxicities.[A714, A228543] Thalidomide and its analogues, including lenalidomide, are referred to as immunomodulatory imide drugs (also known as cereblon modulators), which are a class of immunomodulatory drugs that contain an imide group. Lenalidomide works through various mechanisms of actions that promote malignant cell death and enhance host immunity
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Lenalidomide {u} (Compound) resembles {v} (Compound) Thalidomide
Lenalidomide {u} (Compound) resembles {v} (Compound) Pomalidomide
Lenalidomide {u} (Compound) treats {v} (Disease) hematologic cancer
Lenalidomide {u} (Compound) binds {v} (Gene) PTGS2
Lenalidomide {u} (Compound) upregulates {v} (Gene) RRP8
Lenalidomide {u} (Compound) downregulates {v} (Gene) GDF15
Lenalidomide {u} (Compound) causes {v} (Side Effect) Cholecystitis
Lenalidomide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Warfarin
Lenalidomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cabozantinib
Lenalidomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Chloramphenicol
Lenalidomide (Compound) resembles Thalidomide (Compound)
Lenalidomide (Compound) resembles Pomalidomide (Compound)
Lenalidomide (Compound) treats hematologic cancer (Disease)
Lenalidomide (Compound) binds PTGS2 (Gene)
Lenalidomide (Compound) upregulates RRP8 (Gene)
Lenalidomide (Compound) downregulates GDF15 (Gene)
Lenalidomide (Compound) causes Cholecystitis (Side Effect)
Lenalidomide may cause a minor interaction that can limit clinical effects when taken with Warfarin
Lenalidomide may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Lenalidomide may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol